|
43 Companies |
|
40 Products |
|
40 Products |
|
30 Mechanisms of Action |
|
1 Trial |
|
293 News |
|
| «1234567» |
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment change, Trial withdrawal: Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Apr 20, 2016
P3, N=0, Withdrawn, Sponsor: Shandong University
N=240 --> 0 | Recruiting --> Withdrawn
- | dexamethasone injection / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP (clinicaltrials.gov) - Apr 20, 2016
P3, N=158, Completed, Sponsor: Shandong University
N=240 --> 0 | Recruiting --> Withdrawn Recruiting --> Completed | N=200 --> 158 | Trial primary completion date: Jul 2013 --> Jul 2014
- dexamethasone / Generic mfg., prednisone / Generic mfg.
Trial completion, Phase classification, Trial primary completion date: GIMEMA: High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov) - Apr 20, 2016
P4, N=261, Completed, Sponsor: Shandong University
Recruiting --> Completed | N=200 --> 158 | Trial primary completion date: Jul 2013 --> Jul 2014 Recruiting --> Completed | Phase classification: PN/A --> P4 | Trial primary completion date: Sep 2012 --> May 2014
- ||||| Tavalisse (fostamatinib) / Rigel
Enrollment closed: A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Apr 7, 2016
P3, N=75, Active, not recruiting, Sponsor: Rigel Pharmaceuticals
Recruiting --> Completed | Phase classification: PN/A --> P4 | Trial primary completion date: Sep 2012 --> May 2014 Recruiting --> Active, not recruiting
- Enrollment change, Trial termination, Trial primary completion date: Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome (clinicaltrials.gov) - Mar 23, 2016
P4, N=7, Terminated, Sponsor: Vanderbilt University
Recruiting --> Active, not recruiting N=16 --> 7 | Recruiting --> Terminated | Trial primary completion date: Feb 2016 --> Jul 2015; Difficulty recruiting.
- ||||||| Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial completion: Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Feb 27, 2016
P3, N=313, Completed, Sponsor: Amgen
N=16 --> 7 | Recruiting --> Terminated | Trial primary completion date: Feb 2016 --> Jul 2015; Difficulty recruiting. Enrolling by invitation --> Completed
- Enrollment closed, Trial primary completion date: Prospective Randomized Study of PTC and EUS-guided Drainage of the Bile Duct (clinicaltrials.gov) - Feb 27, 2016
P=N/A, N=110, Active, not recruiting, Sponsor: Institut Paoli-Calmettes
Enrolling by invitation --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Feb 2016
- cetirizine oral / Generic mfg.
Trial primary completion date: Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching (clinicaltrials.gov) - Feb 22, 2016
P4, N=73, Recruiting, Sponsor: Virginia Commonwealth University
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2014 --> Feb 2016 Trial primary completion date: Oct 2016 --> Oct 2017
- ||||||| Trial completion, Enrollment change, Trial primary completion date: IGIV Study for Chronic ITP Patients Ages 3-70 (clinicaltrials.gov) - Feb 21, 2016
P3, N=58, Completed, Sponsor: Grifols Biologicals Inc.
Trial primary completion date: Oct 2016 --> Oct 2017 Recruiting --> Completed | N=75 --> 58 | Trial primary completion date: Mar 2017 --> Mar 2012
- linerixibat (GSK2330672) / GSK
Trial completion, Enrollment change: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus (clinicaltrials.gov) - Feb 5, 2016
P2, N=10, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed | N=75 --> 58 | Trial primary completion date: Mar 2017 --> Mar 2012 Active, not recruiting --> Completed | N=40 --> 10
- Enrollment change: Breastfeeding Support Intervention in Jaundiced Infants (clinicaltrials.gov) - Jan 30, 2016
P=N/A, N=99, Completed, Sponsor: Children's Hospital of Eastern Ontario
Active, not recruiting --> Completed | N=40 --> 10 N=124 --> 99
- Enrollment closed: Single Incision Versus Standard Laparoscopic Splenectomy (clinicaltrials.gov) - Jan 28, 2016
P=N/A, N=30, Active, not recruiting, Sponsor: Children's Mercy Hospital Kansas City
N=124 --> 99 Recruiting --> Active, not recruiting
- BI 655064 / AbbVie, Boehringer Ingelheim
Enrollment change: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (clinicaltrials.gov) - Jan 28, 2016
P1, N=6, Active, not recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Active, not recruiting N=10 --> 6
- ||||| Tavalisse (fostamatinib) / Rigel
Enrollment closed: A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Jan 15, 2016
P3, N=75, Active, not recruiting, Sponsor: Rigel Pharmaceuticals
N=10 --> 6 Recruiting --> Active, not recruiting
- Trial primary completion date: Honey in Chronic Immune Thrombocytopenia (clinicaltrials.gov) - Dec 29, 2015
P2, N=30, Suspended, Sponsor: mamdouh abdulmaksoud abdulrhman
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2014 --> Jan 2016
- | Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial completion, Trial primary completion date: Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training (clinicaltrials.gov) - Dec 23, 2015
P=N/A, N=41, Completed, Sponsor: Amgen
Trial primary completion date: Nov 2014 --> Jan 2016 Recruiting --> Completed | Trial primary completion date: Apr 2016 --> Nov 2015
- lovastatin / Generic mfg.
Enrollment closed, Trial primary completion date: NeuSTART2: Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2 (clinicaltrials.gov) - Dec 9, 2015
P2, N=164, Active, not recruiting, Sponsor: Mitchell S Elkind
Recruiting --> Completed | Trial primary completion date: Apr 2016 --> Nov 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Dec 2015
- Enrollment change, Trial initiation date, Trial primary completion date, Head-to-Head: Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) - Nov 22, 2015
P3, N=8, Terminated, Sponsor: Octapharma
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Dec 2015 N=112 --> 8 | Initiation date: Dec 2006 --> May 2007 | Trial primary completion date: May 2008 --> Feb 2008
- |||| Tavalisse (fostamatinib) / Rigel
Trial primary completion date: A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Nov 17, 2015
P3, N=75, Recruiting, Sponsor: Rigel Pharmaceuticals
N=112 --> 8 | Initiation date: Dec 2006 --> May 2007 | Trial primary completion date: May 2008 --> Feb 2008 Trial primary completion date: Oct 2015 --> Mar 2016
- |||| Tavalisse (fostamatinib) / Rigel
Trial primary completion date: A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Nov 17, 2015
P3, N=75, Recruiting, Sponsor: Rigel Pharmaceuticals
Trial primary completion date: Oct 2015 --> Mar 2016 Trial primary completion date: Oct 2015 --> Jun 2016
- BI 655064 / AbbVie, Boehringer Ingelheim
Enrollment closed: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (clinicaltrials.gov) - Nov 15, 2015
P1, N=10, Active, not recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Oct 2015 --> Jun 2016 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change: Metal or Plastic Stents to Relieve Obstruction of Obstructive Jaundice Prior to Resection of Periampullary Tumors. (clinicaltrials.gov) - Oct 22, 2015
P2, N=92, Completed, Sponsor: Karolinska University Hospital
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed | N=50 --> 92
- | linerixibat (GSK2330672) / GSK
Enrollment closed, Trial primary completion date: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus (clinicaltrials.gov) - Sep 21, 2015
P2, N=40, Active, not recruiting, Sponsor: GlaxoSmithKline
Enrolling by invitation --> Completed | N=50 --> 92 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Oct 2015
- | morphine sulphate / Generic mfg.
Trial completion: Comparison of Epidural Oxycodone and Epidural Morphine (clinicaltrials.gov) - Sep 4, 2015
P3, N=100, Completed, Sponsor: KK Women's and Children's Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Oct 2015 Recruiting --> Completed
- ||||||| Promacta (eltrombopag) / Novartis
Trial completion, Trial primary completion date: EXTEND (Eltrombopag Extended Dosing Study) (clinicaltrials.gov) - Aug 17, 2015
P3, N=302, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Jul 2015
- blisibimod (A-623) / Anthera Pharma
Enrollment change, Trial withdrawal: MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP (clinicaltrials.gov) - Aug 12, 2015
P2/3, N=0, Withdrawn, Sponsor: Anthera Pharmaceuticals
Active, not recruiting --> Completed | Trial primary completion date: Feb 2015 --> Jul 2015 N=60 --> 0 | Not yet recruiting --> Withdrawn
- |||| Korsuva IV (difelikefalin IV) / Cara Therap, Maruishi Pharma, Vifor
Trial completion: Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus (clinicaltrials.gov) - Aug 5, 2015
P2, N=89, Completed, Sponsor: Cara Therapeutics, Inc.
N=60 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- danazol oral / Generic mfg.
Trial primary completion date: Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) - Jul 20, 2015
P2, N=25, Recruiting, Sponsor: Beth Israel Medical Center
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2020
- ||||||| Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial completion: Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients (clinicaltrials.gov) - Jul 15, 2015
P3, N=62, Completed, Sponsor: Amgen
Trial primary completion date: Dec 2015 --> Dec 2020 Active, not recruiting --> Completed
- linerixibat (GSK2330672) / GSK
Phase classification: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus (clinicaltrials.gov) - Jul 13, 2015
P2, N=40, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Phase classification: P1 --> P2
- Trial primary completion date: Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome (clinicaltrials.gov) - Jul 10, 2015
P4, N=16, Recruiting, Sponsor: Vanderbilt University
Phase classification: P1 --> P2 Trial primary completion date: Feb 2015 --> Feb 2016
- Korsuva IV (difelikefalin IV) / Cara Therap, Maruishi Pharma, Vifor
Enrollment closed: Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus (clinicaltrials.gov) - Jul 8, 2015
P2, N=84, Active, not recruiting, Sponsor: Cara Therapeutics, Inc.
Trial primary completion date: Feb 2015 --> Feb 2016 Recruiting --> Active, not recruiting
- linerixibat (GSK2330672) / GSK
Trial primary completion date: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus (clinicaltrials.gov) - Jun 22, 2015
P1, N=40, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2015 --> Apr 2016
- BI 655064 / AbbVie, Boehringer Ingelheim
Trial primary completion date: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (clinicaltrials.gov) - Jun 11, 2015
P1, N=10, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Apr 2015 --> Apr 2016 Trial primary completion date: Feb 2016 --> May 2016
- |||| tradipitant (VLY-686) / Vanda
Trial completion: Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis (clinicaltrials.gov) - Jun 3, 2015
P2, N=69, Completed, Sponsor: Vanda Pharmaceuticals
Trial primary completion date: Feb 2016 --> May 2016 Recruiting --> Completed
- Enrollment change: Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions (clinicaltrials.gov) - May 22, 2015
P1/2, N=28, Terminated, Sponsor: University of Michigan
Recruiting --> Completed N=50 --> 28
- ||| Trial completion: Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) (clinicaltrials.gov) - May 14, 2015
P1, N=52, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=50 --> 28 Active, not recruiting --> Completed
- |||| Trial primary completion date: IGIV Study for Chronic ITP Patients Ages 3-70 (clinicaltrials.gov) - May 8, 2015
P3, N=75, Recruiting, Sponsor: Grifols Biologicals Inc.
Active, not recruiting --> Completed Trial primary completion date: Mar 2014 --> Mar 2017
- Enrollment open, Trial initiation date, Trial primary completion date: FOX-TREG: Study of the Role of Regulator T Cells in the Pathophysiology of Childhood Henoch Schönlein Purpura (clinicaltrials.gov) - Apr 23, 2015
P=N/A, N=120, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Trial primary completion date: Mar 2014 --> Mar 2017 Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Feb 2015 | Trial primary completion date: Sep 2017 --> Feb 2017
- dexamethasone / Generic mfg., prednisone / Generic mfg.
Trial primary completion date: GIMEMA Protocol ITP0207: Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura (clinicaltrials.gov) - Apr 22, 2015
P3, N=150, Recruiting, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
Not yet recruiting --> Recruiting | Initiation date: Sep 2015 --> Feb 2015 | Trial primary completion date: Sep 2017 --> Feb 2017 Trial primary completion date: Mar 2015 --> Mar 2016
- | prednisone / Generic mfg., cyclosporin A microemulsion / Generic mfg., hydrocortisone / Generic mfg.
Enrollment closed: Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) - Apr 22, 2015
P3, N=62, Active, not recruiting, Sponsor: Ohio State University
Trial primary completion date: Mar 2015 --> Mar 2016 Recruiting --> Active, not recruiting
- Trial completion: NATURAL KILLER CELLS IN IMMUNOLOGIC THROMBOCYTOPENIC PURpura of Adults (clinicaltrials.gov) - Apr 22, 2015
P=N/A, N=80, Completed, Sponsor: Assistance Publique Hopitaux De Marseille
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion, Enrollment change, Trial primary completion date: Covered vs. Uncovered SEMS for Occluded Biliary Metal Stents (clinicaltrials.gov) - Apr 21, 2015
P4, N=43, Completed, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed Recruiting --> Completed | N=60 --> 43 | Trial primary completion date: Apr 2013 --> Nov 2014
- Enrollment change, Trial withdrawal, Trial primary completion date: Vulvar Contact Dermatitis Resulting From Urine Incontinence (clinicaltrials.gov) - Apr 8, 2015
P=N/A, N=0, Withdrawn, Sponsor: Meir Medical Center
Recruiting --> Completed | N=60 --> 43 | Trial primary completion date: Apr 2013 --> Nov 2014 N=400 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Mar 2013 --> Mar 2012
- ondansetron / Generic mfg., morphine sulphate / Generic mfg.
Trial completion: Prevention of Intrathecal Morphine Induced Pruritus: Comparison of Ondansetron and Palonosetron (clinicaltrials.gov) - Apr 1, 2015
P=N/A, N=80, Completed, Sponsor: Kyungpook National University
N=400 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Mar 2013 --> Mar 2012 Recruiting --> Completed
- || Enrollment closed: Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) (clinicaltrials.gov) - Apr 1, 2015
P1, N=52, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Recruiting --> Active, not recruiting
- acetylcysteine solution / Generic mfg.
Enrollment status, New P1 trial, Trial primary completion date: NACinTTP: A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia Purpura (clinicaltrials.gov) - Mar 26, 2015
P0, N=3, Enrolling by invitation, Sponsor: Puget Sound Blood Center
Recruiting --> Active, not recruiting Recruiting --> Enrolling by invitation | Trial primary completion date: May 2014 --> May 2016
- Trial completion: Pruritus in Patients With Chronic Kidney Disease (clinicaltrials.gov) - Mar 17, 2015
P=N/A, N=108, Completed, Sponsor: Far Eastern Memorial Hospital
Recruiting --> Enrolling by invitation | Trial primary completion date: May 2014 --> May 2016 Recruiting --> Completed
- |||| Promacta (eltrombopag) / Novartis
Trial completion, Trial primary completion date: A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Mar 12, 2015
P4, N=167, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Apr 2015 --> May 2014
- ||| Trial completion: Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis (clinicaltrials.gov) - Feb 8, 2015
P1, N=690, Completed, Sponsor: Taro Pharmaceuticals USA
Active, not recruiting --> Completed | Trial primary completion date: Apr 2015 --> May 2014 Active, not recruiting --> Completed